Web Desc
Obesity and NAFLD: Mechanisms and Therapeutics
Scientific Organizers: Rebecca A. Haeusler, Shingo Kajimura and Alexei Kharitonenkov
Date: February 23 - 27, 2020
Location: Fairmont Banff Springs, Banff, AB, Canada
Sponsored by AstraZeneca, Gilead Sciences, Inc., Merck & Co., Inc. and Novo Nordisk A/S
For important information on the coronavirus, please click here
Summary of Meeting:
Energy metabolism underlies all facets of human health. With the rates of obesity and nonalcoholic fatty liver disease (NAFLD) surging, understanding how energy metabolism is governed in healthy and diseased states is of the utmost concern. The focus of this Keystone Symposia is to bring obesity and NAFLD disease researchers together to identify metabolic disease factors and future directions. Halting the progression of NAFLD into nonalcoholic steatohepatitis (NASH) is considered an unmet need in human health. Therefore, the conference program is designed to discuss both the regulatory elements driving the progression of obesity and NAFLD and the metabolic underpinnings of NASH. The program also includes sessions on metabolites, hormones, and cellular signaling pathways and features cutting edge therapeutic approaches for obesity and NASH. This conference will bring together scientists and physicians specializing in basic, translational, and clinical research, as well as industry scientists, to create a robust exchange of ideas on how to move the field forward.
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: October 23 2019 details
Discounted Abstract Deadline: October 23 2019 details & pricing
Abstract Deadline: November 21 2019 details & pricing
Discounted Registration Deadline: December 19 2019 details & pricing

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.

Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
AstraZenecaGilead Sciences, Inc.Merck & Co., Inc.Novo Nordisk A/S
We gratefully acknowledge additional support from these exhibitors at this conference:
Sable Systems International
We gratefully acknowledge additional support for this conference from:
Cayman Chemical CompanyLipedema FoundationResearch Diets, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:


Novo Nordisk A/S

Pfizer Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 1R13DK123897-01
Funding for this conference was made possible (in part) by 1R13DK123897-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found